iRadimed (NASDAQ:IRMD) vs. Becton, Dickinson and Company (NYSE:BDX) Head-To-Head Analysis

Becton, Dickinson and Company (NYSE:BDX) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Dividends

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.1%. iRadimed pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. iRadimed pays out 42.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 53 consecutive years and iRadimed has increased its dividend for 1 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Becton, Dickinson and Company and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	4.52%	14.79%	6.93%
iRadimed	26.85%	23.90%	20.89%

Earnings & Valuation

This table compares Becton, Dickinson and Company and iRadimed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84 billion	2.50	$1.68 billion	$3.32	59.60
iRadimed	$83.81 million	12.38	$22.48 million	$1.87	43.37

Becton, Dickinson and Company has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Becton, Dickinson and Company and iRadimed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1	8	8	1	2.50
iRadimed	0	2	3	1	2.83

Becton, Dickinson and Company currently has a consensus target price of $185.07, suggesting a potential downside of 6.47%. iRadimed has a consensus target price of $120.00, suggesting a potential upside of 47.95%. Given iRadimed’s stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than Becton, Dickinson and Company.

Risk & Volatility

Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Summary

iRadimed beats Becton, Dickinson and Company on 11 of the 17 factors compared between the two stocks.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.